Virax Biolabs Group Limited (VRAX)
- Previous Close
0.7398 - Open
0.7690 - Bid 0.6536 x 100
- Ask 0.9320 x 100
- Day's Range
0.7401 - 0.8097 - 52 Week Range
0.6000 - 5.4500 - Volume
73,910 - Avg. Volume
36,998 - Market Cap (intraday)
1.89M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-17.7000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
20.00
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.
viraxbiolabs.comRecent News: VRAX
Performance Overview: VRAX
Trailing total returns as of 5/10/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VRAX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VRAX
Valuation Measures
Market Cap
1.89M
Enterprise Value
-3.04M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
20.38
Price/Book (mrq)
0.30
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-70.98%
Return on Equity (ttm)
-134.83%
Revenue (ttm)
79.3k
Net Income Avi to Common (ttm)
-6.92M
Diluted EPS (ttm)
-17.7000
Balance Sheet and Cash Flow
Total Cash (mrq)
5.21M
Total Debt/Equity (mrq)
2.98%
Levered Free Cash Flow (ttm)
-4.1M
Research Analysis: VRAX
Company Insights: VRAX
VRAX does not have Company Insights